Nwbo via dcvax may very well become a king maker, in that it’s looking like dcvax in combo with iCLC and other BP products, yield higher efficacy than without iCLC and dcvax, such as the early promising indications with Keytruda imply. But the same likely applies to combination with BMS’ analogous oncology product. Etc., etc..
So nwbo can play with any and all BPs, as BB once or twice stated.
In fact, it might be too limiting to only collaborate with one BP and possibly impeding the overall progress against a greater variety of cancers.
There may also be a similar approach against non oncology diseases.
From a moral perspective wouldn’t it be too self serving to have a Chosen BP get the secret sauce and control who and how it is applied towards greater potential or not?
Dcvax/Hiltonil may become the new oil that many BP engines will need, so to speak.
Market Data 
Markets 
AI
